ALSERepository of Iași University of Life Sciences, ROMANIA

Insulin choice and treatment protocol for “healthy” diabetic felines

Show simple item record

dc.contributor.author Burlacu, Mădălina
dc.contributor.author Solcan, Gheorghe
dc.date.accessioned 2021-10-06T09:15:27Z
dc.date.available 2021-10-06T09:15:27Z
dc.date.issued 2015
dc.identifier.citation Rosca Burlacu, Madalina, Gheorghe Solcan. 2015. "Insulin choice and treatment protocol for “healthy” diabetic felines". Lucrări Științifice USAMV - Iași Seria Medicină Veterinară 58 (2): 158-163. en_US
dc.identifier.uri https://repository.uaiasi.ro/xmlui/handle/20.500.12811/1891
dc.description.abstract Demand of exogenous insulin administration is currently limited by a series of factors, such as unbalanced pharmacodynamics, low therapeutic index, inconsistent intensity of effect, high physical instability and need for administration by injection. Still, the broad panel of insulin analogues available at the moment has a vital role in the treatment of diabetes mellitus, allowing individualized glycemic control in diabetic cats. The current paper describes the specific treatment protocol for clinically stable diabetic felines, focusing on two types of insulin frequently used in Romania,. Data were collected from the medical records of cats presented at the veterinary teaching hospital of Faculty of Veterinary Medicine of Iasi, Romania. Cases were considered eligible for inclusion in the study if registered with a clear diagnosis of DM and were in a stable clinical condition. Therapeutic protocol focusing on dosing regiments for clinically stable diabetic cats, included two commercially available preparations: glargine and premixed isophane insulin. All cats were treated with both types of insulins and therapy was further continued with the preparation that provided the ideal control of blood glucose level. Diabetes mellitus was diagnosed in 65 cats, of which only 18 were in a stable clinical condition. In 15 cats, ideal control was obtained with insulin glargine, with a median dose of 0.6 IU/kg (range: 0.2-1.1 IU/kg) administered twice daily. Only 3 cases were managed long term with 0.8 IU/kg (0.4-1.9IU/kg) premixed isophane twice daily. The premixed insulin never exceeded a period of action of 8 hours and allowed reinstallation of hyperglycemia on a time interval varying from 2 to 4 hours before the next administration. Insulin glargine provided a good control of blood glucose level, with a very low incidence of subclinical hypoglycaemia episodes and was associated with a higher remission rate of diabetes. Premixed isophane insulin was associated with a blood glucose level to the lower normal range and with frequent hypoglycemia episodes. Also, due to the accelerated metabolism, isophane insulin activity did not reach the second administration in the day, thus cats were hyperglycemic for a varying length of time during the day. en_US
dc.language.iso en en_US
dc.publisher ”Ion Ionescu de la Brad” University of Agricultural Sciences and Veterinary Medicine, Iași en_US
dc.rights Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject feline diabetes en_US
dc.subject glargine en_US
dc.subject hyperglycaemia en_US
dc.subject insulin treatment en_US
dc.subject isophane en_US
dc.title Insulin choice and treatment protocol for “healthy” diabetic felines en_US
dc.type Article en_US
dc.author.affiliation Madalina Rosca Burlacu, Gheorghe Solcan, University of Agronomic Sciences and Veterinary Medicine of Iasi
dc.publicationName Lucrări Științifice USAMV - Iași, Seria Medicină Veterinară
dc.volume 58
dc.issue 2
dc.publicationDate 2015
dc.startingPage 158
dc.endingPage 163
dc.identifier.eissn 2393-4603


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)